Experimental Drug Shrinks Advanced Ovarian Tumors

A Phase I trial combining IACS-6274 with standard therapy produced tumor shrinkage in most patients with advanced ovarian cancer.

Updated on Nov. 19, 2026 in Cancer

Clear glass flask of pale amber liquid on a steel laboratory bench beside pipette tips, with a biosafety cabinet softly out of focus behind.
An experimental drug, IACS-6274, combined with standard chemotherapy shrank advanced ovarian tumors in most of 14 patients in an early-stage trial. AI Illustration. Upload story photo >

An experimental drug, IACS-6274, combined with bevacizumab and paclitaxel shrank tumors in 14 patients with advanced ovarian cancer in an early-stage trial. Researchers also identified loss of the ASNS enzyme as a potential biomarker predicting response.

Why it matters

Only around 15% of women diagnosed with advanced ovarian cancer survive at least five years, so a treatment approach that shrinks tumors in most patients is a notable development. The findings also suggest a way to identify which patients are most likely to benefit.

The Phase I trial enrolled 14 patients, and 9 of 13 patients with CT-measurable tumors had a partial response, with tumors shrinking at least 30%. Whether the response holds in larger populations has not yet been determined, and the results must be confirmed in larger studies.

The players

University of Texas MD Anderson Cancer Center

A major cancer research and treatment institution in Houston, Texas, and the institution of the lead researcher on the trial.

Vall d'Hebron Institute of Oncology

A Barcelona-based cancer research institute whose affiliated chair presided over the symposium where the findings were presented.

The details

Patients received IACS-6274, a glutaminase-1 (GLS1) inhibitor that blocks the glutamine pathway tumors use to survive, twice daily alongside standard bevacizumab and paclitaxel in 21-day cycles. The treatment also shifted the tumor microenvironment toward greater immune system activation.

Timeline

  1. Findings were presented during the week of November 18, 2026, at the 38th EORTC-NCI-AACR Symposium.

  2. Disease control was measured at 12 weeks after treatment began in 85% of patients.

  3. Durable regression or stable disease lasting four months or more was seen in 77% of patients with measurable disease.

Health Landscape

The results extend a research line on targeting tumor glutamine metabolism, a pathway ovarian cancer relies on to survive standard therapies. Linking GLS1 inhibition to ASNS loss moves that approach toward patient selection rather than one-size-fits-all treatment.

For women with advanced ovarian cancer, a treatment that shrinks tumors and a biomarker that could identify likely responders may eventually shape which therapies they are offered. The approach remains in early testing and is not yet available outside clinical trials.

The takeaway

Targeting metabolic dependencies in tumors may pair well with standard chemotherapy, and biomarkers like ASNS loss could help match patients to therapies. Larger studies will determine whether these early responses translate into lasting benefit.

What happens next

A further 15 patients are due to receive treatment in the clinical trial, with another 15 to be treated if results remain positive.

Further reading

Explore more cancer research news for context on emerging treatment approaches.

Source note: This article includes information reported by Inside Precision Medicine.